Amneal Pharmaceuticals
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and ...
Latest News
13 days ago · zacks.com
AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance RaisedAmneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.
13 days ago · seekingalpha.com
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call TranscriptAmneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
14 days ago · marketbeat.com
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings CallAmneal Pharmaceuticals NASDAQ: AMRX reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an expected decline at its AvKARE business. Adjusted EBITDA rose 30% to $207 million, while adjusted earnings per share increased 53% to $0.26.
14 days ago · zacks.com
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
14 days ago · zacks.com
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top EstimatesAmneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.17 per share a year ago.
14 days ago · globenewswire.com
Amneal Reports Third Quarter 2026 Financial Results– Q3 2026 Net Revenue of $863 million ; GAAP Net Loss of $22 million ; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million ; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Year Guidance –
21 days ago · zacks.com
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
21 days ago · zacks.com
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?Here is how Amneal Pharmaceuticals (AMRX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
21 days ago · zacks.com
Implied Volatility Surging for Amneal Pharmaceuticals Stock OptionsInvestors need to pay close attention to AMRX stock based on the movements in the options market lately.
22 days ago · zacks.com
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove AMRX